New data from AstraZeneca's FASLODEX studies on breast cancer to be presented at SABSC

Published on December 5, 2012 at 4:28 AM · No Comments

AstraZeneca (NYSE: AZN) today announced the presentation of important new data from studies of FASLODEX® (fulvestrant) Injection at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium taking place from 4-8 December at the Henry B. Gonzalez Convention Center, San Antonio, Texas. This will include final analysis of overall survival from the Phase III CONFIRM trial (COmparisoN of Faslodex In Recurrent or Metastatic breast cancer) comparing fulvestrant 500 mg vs 250 mg.

FASLODEX 500 mg is indicated for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy. FASLODEX is contraindicated in patients with known hypersensitivity to the drug or to any of its components. Hypersensitivity reactions, including urticaria and angioedema have been reported in association with FASLODEX.

"The study data and research findings that will be presented are a further addition to AstraZeneca's ongoing commitment to the continued study and evaluation of treatment options for metastatic breast cancer. While some of the data and research are investigational, it highlights AstraZeneca's ongoing pursuit to developing and optimizing breast cancer treatments for patients," said Yuri Rukazenkov, MD, Medical Science Director, AstraZeneca.

Highlighted study results to be presented:

  • Final overall survival analysis of CONFIRM, a Phase III, randomized, double-blind, parallel-group, multicenter trial comparing FASLODEX 500 mg>

Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg. (Abstract #S1-4). SABSC press briefing, Wednesday, December 5, 7:30 AM CDT. Oral presentation, General Session 1, Wednesday, December 5, 9:15 AM CDT, Exhibit Hall D.

  • Data will be presented from a study on overcoming PTEN loss-related endocrine therapy resistance through strategic combinations with mTOR, AKT, or MEK inhibitors.

Overcoming endocrine therapy resistance related to PTEN loss by strategic combinations with mTOR, AKT, or MEK inhibitors. (Abstract #PD01-01). Poster Discussion 1, Endocrine Resistance, Wednesday, December 5, 5:00 - 7:00 PM CDT, Ballroom A.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment